Post on 16-Jul-2015
Transdermal drug delivery system
2
Transdermal Therapeutic Systems
Diffusion of the medication (drug) through skin into
the systemic circulation for distribution and
therapeutic effect
Most TDD systems use passive delivery
3
13.1 Advantages of TTS’s13.1 Advantages of TTS’s
1. Eliminates oral absorption variables.
2. Eliminates first-pass metabolism
3. Provides controlled constant drug.
4. Can accommodate potent drugs
5. Permits self-administration
6. Non-invasive (no needles or injections)
7. Improves patient compliance
8. Easy treatment termination
4
Limitations of TDD Systems
• Poor diffusion of large molecules
• Skin irritation
5
• Therapeutic indication• Desired drug delivery profile
- Dose level, duration, etc.• Skin adhesion profile• Application site• Ease of application• Patch size, shape, appearance, comfort• Wear period• Packaging• Patch disposal• Patch cost
TDD System Design Factors
6
Process of transdermal permeation.
7
BASIC COMPONENTS OF TDDS 1.Polymer matrix
2.The drug 3.Permeation enhancers 4.Other excipients1.Polymer matrixIdeal polymer ٠MWT,and chemical functionality of the polymer should not affect the
diffusivity of drug and its release ٠stable ٠non reactive ٠easily manufactured ٠easily fabricated into desired product ٠inexpensive ٠degaradation product must be non toxic or non antagonistic to the host ٠ should retain its mechanical properties when the large amount of drug is loaded in to it
8
Polymers used in TDDS• Natural polymers
– Cellulose derivatives– Zein– Gelatin– Shellac– Waxes– Proteins– Gums– Natural rubbers– starch
• Synthetic elastomers --polybutadiene --hydrin rubber --polysiloxone --silicone rubber --nitrile --acrylonitrile --butyl rubber --styrene butadiene rubber --neoprine etc.
• Synthetic polymers PVA,PVC,PE,PP,Poly amide,Poly acrylate,Polyurea,PVP,PMMA,Epoxy etc.
9
2. Suitable drug candidate• Physico chemical properties of drug
– Should have MW less than 1000 daltons(800-1000)– Should have affinity for both lipophilic and hydrophilic phases– Should have low melting pont
• Biological properties of drug– Should be potent(less than 20mg)– Half life should be short– Must not induce a cutaneous irritant or allergic response– Drugs which degrade in the GI tract or inactivated by hepatic
first pass effect are suitable candidate– Tolerance to the drug must not develop – Drugs which has to be administered for a longer period of time
can be formulated – Drugs which cause adverse effects to non target tissues can
also be formulated
10
3.PERMEATION ENHANCERS(to enhance stratum corneum permeability)
• Solvents Increases penetration by swelling the polar pathway transport or fluidising lipids Eg.water,ethanol,methanol,DMS,homologs of methyl sulphoxide,dimethyl
acetamide,and DMF,2-pyrrolidone,N-methyl,2-pyrrolidone,laurocapram,PG,glycerol,silicone fluids,isopropyl palmitate.
• Surfactants Enhances the polar pathway transport of hydrophilic drugs• Anionic surfactants Dioctyl sulpho succinate,SLS,deco decylmethyl sulphoxide etc.• Non ionic surfactants Pluronic F127,Pluronic F68,etc.• Bile salts Sodium taurocholate,sodium deoxy cholate,sodium tauroglycocholate.• Binary systems Propylene glucol-oleic acid and 1,4-butane diol-linoleic acid• Miscellaneous Urea-hydrating and keratolytic agent,N,N-dimethyl-m-toluamide,calcium
thioglycolate,anti cholinergic agents• Potential permetion enhancers Euclyptol,di-o-methyl-ß-cyclodextrin and soyabean casein
11
Permeability Coefficient Is the Critical Predictor of Transdermal Delivery
Transport = Flux = (mg/cm2/sec) = P x A x (Cd – Cr)
Permeability Coefficient = P = D x K (cm/sec) h
Where A = Surface area of patchD = Diffusivity of drug in membrane (skin)K = Partition coefficient (patch/skin)C = Concentration in donor or receptor
(patch or skin)h = Thickness of membrane (skin)
12
4.OTHER EXCIPIENTS• AdhesivesIdeal properties• Should not irritate or sensitize the skin or affect normal functions of the skin• Should adhere to the skin aggressively• Should be easily removed• Should not leave an un washable residue on the skin• Should have an intimate contact with the skin • Should be compatible with the drug,excipients and permeation enhancers• Permeation of drug should not be affected• Backing membraneIdeal properties• Flexible and provide good bond to the drug reservoir• Prevent drug from leaving the dosage form• Should be impermeable• E.g.metallic plastic laminate,plastic backing with absorbent pad and
occlusive base plate,adhesive foam pad with occlusive base plate.
13
• Liner: Protects the drug during storage and is removed prior to use
• Drug
• Adhesive: Serves to bind the components of the patch to the skin
• Membrane: Controls the release of the drug from the reservoir in certain types of patches
• Backing: Protects the patch from the outer environment.
14
Formulation of TDDS1.Membrane-moderated or permeation controlled TDDS
• Drug reservoir(homogenous dispersion of drug with polymeric matrix or suspension of drug in un leachable viscous liquid medium such as silicone fluid) is encapsulated within drug impermeable metallic plastic laminate and a rate controlling polymeric membrane(ethylene vinyl acetate co polymer)
• The cross sectional view of this system is shown in the following Fig.1
15
Reservoir Patches
• The reservoir system has a drug layer that is separate from the adhesive.
16
Film Backing
Drug Layer
Protective Peel Strip (removed prior to use)
skin
Schematic Drawing of the Reservoir type of patch.
Rate-controlling Membrane
Contact Adhesive
17
• Drug molecule are permitted to release through this rate controlling membrane
• A thin layer of silicone or poly acrylate adhesive may be applied to the external surface of the rate controlling membrane to achieve intimate contact of the TDDS and the skin surface
• Release rate of this TDDS depends upon the polymer composition,permeability co efficient and thickness of the rate cotrolling membrane and adhesive
• The intrinsic rate of drug release from this TDDS is calculated by the following formula.1
CR
dQ/dt= -------------------- 1/Pm+1/Pa
18
Where
CR-con.of drug in the reservoir compartment
Pm-permeability co efficient of rate controlling polymeric membrane Pa- permeability co efficient of adhesive
For microporous membrane Km/r. Dm
Pm = -------------------- hm
Ka/m. Da
Pa = -------------------- ha
Substituting these values in formula.1, it becomes
Km/r .Ka/m .Dm.Da
dQ/dt= ---------------------------------------------CR
Km/r. Dm.ha + Ka/m. Da. hm
19
Where• Km/r --partition co-efficient of drug between membrane and reservoir
• Ka/m --partition co-efficient of drug between adhesive and membrane
• Dm --diffusion co-efficient of drug in the membrane
• Da -- diffusion co-efficient of drug in the adhesive
Example of this system are
1.Nitro glycerin releasing TDDS (Transderm-Nitro/ciba,USA)for once a day medication in angina pectoris
2.Scopolamine releasing TDDS (Transderm-Scop/ciba,USA)for 72 hrs.prophylaxis of motion sickness
3. Estradiol releasing TDDS (Estraderm/ciba)for treatment of menopausal syndrome
4. Clonidine releasing TDDS (Catapres/Boehringer Ingelheim)for 7 day therapy of hyper tension
5. Prostaglandin-derivatives TDDS
20
2.Adhesive diffusion/dispersion-controlled TDDS
Drug reservoir• homogenous dispersion of drug with adhesive polymer(poly(isobutylene) or
poly acrylate)
• Then spreading of this medicated adhesive polymer on flat sheet of drug impermeable metallic plastic backing to form thin drug reservoir layer
• On top of the drug reservoir layer,thin layers of rate controlling adhesive polymer of specific permeability and constant thickness are applied to produce an adhesive diffusion/dispersion-controlled TDDS
• The cross sectional view of this system is shown in the following Fig.2
21
Drug in Adhesive Patches
• A system in which the drug is incorporated directly into the adhesive, rather than into a separate layer. Usually used for smaller molecular weight compounds.
• These can be either a single layer or multi-layer.
• Sometimes referred to as the “matrix type patch”
22
Film Backing
Drug/Adhesive Layer
Protective Liner (removed prior to use)
skin
Schematic Drawing of the Matrix (Drug-in-Adhesive) type of patch.
23
• The rate of drug release in this system is defined by
Ka/r.Da
dQ/dt= -----------------CR
ha
WhereKa/r-partition co-efficient of drug bw adhesive layer and reservoir layer
Da-diffusion co-efficient of drug in the adhesive layer
ha-thickness of adhesive layer
Examples for this system1.Iso sorbide dinitrate-releasing TDDS 2.Verapamil releasing TDDS
24
• 3.Matrix diffusion-controlled TDDS
Drug reservoir
• homogenous dispersion of drug with hydrophilic or lipophilic polymer matrix by any one of the following methods
• Homogenous dispersion of finely ground drug particles with liquid polymer or highly viscous base polymer followed by cross linking of polymer chains
• Homogenous mixing of drug solid with rubbery polymer at an elevated temperature
• Dissolving the drug and polymer in a common solvent follwed by solvent evaporation in a mould at an elevated temperature or under vaccum.
• Medicated polymer is moulded in to desired surface area and controlled thickness
• This medicated polymer disc is pasted on to an occlusive base plate with impermeable plastic backing
• Then the adhesive polymer is spread along the circumference to form a strip of adhesive rim around the medicated disc
25
• the rate of drug release from this sytem is defined as
A Cp DpDq/dt = [ ---------------------] 1/2
2t where
A initial drug loading doseCp and Dp are solubility and diffusivity of drug in poymer matrix
the rate of drug release from this system at steady state is defined as
Q/t1/2= [(2A-Cp) Cp Dp] 1/2
26
Example of this system are
1.Nitro glycerin releasing TDDS (Nitro-Dur and Nitro-Dur II /Key pharmaceuticals,USA)
2. Estradiol di acetate releasing TDDS
3. Verapamil releasing TDDS
The cross sectional view of this system is shown in the following Fig.3
27
4.Micro reservoir type/micro sealed dissolution- controlled TDDS
Combination of the reservoir and matrix diffusionDrug reservoir•suspension of drug with aqueous solution of water soluble liquid polymer
•Homogenous dispersion of drug suspension in a lipophilic polymer(silicone elastomer)
•As a result discrete un leachable microscopic spheres of drug reservoir is formed which is stabilized by cross linking
•Medicated polymer is moulded in to desired surface area and controlled thickness and it is coated with a layer of bio compatible polymer to modify mechanism and rate of drug release
•This medicated polymer disc is pasted on to an occlusive base plate with impermeable plastic backing
•Then the adhesive polymer is spread along the circumference to form a strip of adhesive rim around the medicated disc
Example of this system are
1.Nitro glycerin releasing TDDS (Nitrodisc /searle,USA)
The cross sectional view of this system is shown in the following Fig.4
1.Nitro glycerin releasing TDDS (Nitro-Dur and Nitro-Dur II /Key pharmaceuticals,USA)
2. Estradiol di acetate releasing TDDS
3. Verapamil releasing TDDS
28
29
Products on the market, or in development include:
• Clonidine• Works as an agonist of adrenaline at the
presynaptic α2 adrenergic
• Product name = Catapres-TTS®
• used to treat hypertension
30
• Ethinylestradiol (EO) and norelgestromin (N)• Product name = Ortho-Evra®
• Used for Contraception• Type of patch = Drug-in-Adhesive
• Frequency of application = weekly
31
• Fentanyl
• Product Name = Duragesic®
• Used for: Analgesia• Type of Patch = Drug-in-Adhesive• Frequency of Application = Weekly
32
• Lidocaine• Product Name = Lidoderm®
• Used for: analgesia of postheretic neuralgia (PHN), a painful condition caused by the varicella zoster virus (herpes zoster = shingles)
• Type of Patch = Reservoir• Frequency of Application = Daily
33
• Nicotine
• Product name = Habitrol®, Nicoderm – CQ®, Nicotrol®, Prostep®
• Used for: Smoking cessation
• Frequency of administration = Daily
34
• Nitroglycerin• Works by producing nitric oxide (NO), which then acts as
a vasodilator• Product Names = Nitro-Dur®, Transderm-Nitro®
• Used for: Angina• Type of Patch = Nitro-Dur is Drug-in-adhesive Nitrodisc is reservoir• Frequency of administration = Daily
35
• Estradiol• Product Name = Alora®, Climara®, Esclim®,
Estraderm®, FemPatch®, Vivelle®, Vivelle-DOT®
• Used for: Hormone replacement• Type of Patch: Drug-in-adhesive• Frequency of application = weekly
36
• Estradiol + Norethindrone• Product name = CombiPatch®
• Used for: Hormone Replacement
37
• Oxybutynin• Works as competitive antagonist of the
muscarinic acetycholine receptor• Product name = Oxytrol®
• Used for: Overactive bladder (antispasmodic)• Type of Patch: Drug-in-adhesive• Frequency of application = twice a week
38
• Scopolamine• Works as competitive antagonist of acetylcholine
at the muscarinic receptor• Product Name = Transderm Scop®
• Used for: Motion Sickness
39
• Testosterone
• Product Names = Androderm®, Testoderm TTS®, Testoderm®
• Used for: Hypogonadism
40
• Lidocaine + Epinephrine
• Product name = Lidosite
• Used for: Dermal anesthesia
• Type of Patch = Reservoir, iontophoretic.
Epinephrine acts as vasoconstrictor, thus prolonging the duration of action of lidocaine (by delaying resorption) at the site
41
Manufacturer Trade name Drug Strength available
Ciba
Estraderm Estradiol 25 μg, 50 μg, 100 μg
Transderm-Scop Scopolamine 1.5 mg
Transderm-Nitro Nitroglycerin 0.1 mg, 0.2 mg
Janssen Duragesic Fentanyl 25 μg, 50 µg, 100 μg
Basel Habritol Nicotine 21 μg
Parke-Davis Nicotrol Nicotine 21 μg
Lederle Prostep Nicotine 21 μg
42
TTS Available in market
Large scale mfg of TTS
43
Physical parameters Evaluation of adhesiveIn-vitro testingIn-vivo assessmentCutaneous metabolismStability studiesEvaluation of skin reactions.
Evaluation Parameters
09/30/14 43
44
Thickness
09/30/14 44
45
Weight variation
09/30/14 45
46
Folding endurance
09/30/14 46
47
Moisture content
09/30/14 47
% Moisture content = Initial weight – Final weight X 100 Final weight
Moisture content
% Moisture content = Initial weight – Final weight X 100 Final weight
48
Moisture uptake
09/30/14 48
% moisture uptake = Final weight – Initial weight X 100 Initial weight
49
Flatness
09/30/14 49
% constriction = I1 – I2 X 100 I1
I2 = Final length of each stripI1 = Initial length of each strip
50
Drug content
09/30/14 50
51
Water Vapor Transmission studies
09/30/14 51
52
Evaluation of adhesive
1} Peel adhesion properties
09/30/14 52
It is the force required to remove adhesive from test substrate.
53
2} Tack properties
It is the ability of the polymer to adhere to substrate with little contact pressure.
2.1} Thumb tack test
2.2} Rolling ball tack test
09/30/14 53
54
2.3}Quick-stick (or peel-tack) test
09/30/14 54
55
2.4} Probe tack test
09/30/14 55
56
3} Shear strength properties
09/30/14 56
Shear strength is the measurement of the cohesive strength of adhesive polymer.
57
Tensile strength
09/30/14 57
Tensile strength= F/a.b (1+L/l)
F - the force required to break a - width of film b - thickness of film L - length of film l - elongation of film at break point
58
In-vitro testing
The Paddle over Disc
The Cylinder modified USP Basket
The reciprocating disc
Diffusion Cells e.g. Franz Diffusion Cell and its modification
Keshary- Chien Cell
09/30/14 58
59
In-vitro testing
Importance
(1)Defining skin permeation kinetic studies using a diffusion cell system and cadaver skin during the drug development process.
(2) in vitro drug release kinetics, to be used for batch-to-batch release and as a compendial test.
09/30/14 59
Preparation of skin for permeation studies
• Intact Full thickness skin
• Separation of epidermis from full thickness skin:
60
61
K-C cell for permeation studies
09/30/14 61
62
Effect of skin uptake metabolism
63
64
In-vivo assessment
1} Animal model
Mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea pig
09/30/14 64
65
In-vivo assessment
2} Human model
. Phase I clinical trials are conducted to determine mainly safety in volunteers.
Phase II clinical trials determine short term safety and mainly effectiveness in patients.
Phase III trials indicate the safety and effectiveness in large number of patient population.
Phase IV trials at post marketing surveillance are done for marketed patches to detect adverse drug reactions.
09/30/14 65
Skin irritation studies
• Group I was served as normal, without any treatment.
• Group II, control, was applied with marketed adhesive tape.
• Group III Transdermal systems (blank)• Group IV Transdermal systems (drug
loaded)• Group V standard irritant .
66
Contact dermatitis
67
Evaluation of skin reactions.
09/30/14 67
68
Stability studies
09/30/14 68
Study Storage conditions Time period
Temperature Relative humidity
Long Term 25°C± 2°C OR
30°C± 2°C
60%± 5% OR
65%± 5%
12 months
Intermediate 30°C± 2°C 65%± 5% 6 months
Accelerated 40°C± 2°C 75%± 5% 6 months
69
70
APPLICATIONS
09/30/14 70
71
The Past
• 3000 BC--Pharmaceuticals and plasters first recorded in Babylonia.
• 1500 BC--Plasters recorded in the Ebers Papyrus (Egypt).
• Plasters made by physicians or pharmacists at the time of dispensing
09/30/14 71
72
The Past
• Used for topical and deep tissues• Counterirritants, protective dressings, belladonna,
salicylic acid, flaxseed, mustard, • Adhered to skin with stiff ointments, waxes,
melted waxes and rubber resins, kaolin• Applied hot, could absorb water • Backings made of cloth or animal skin
Plasters, Poultices and CeratesPlasters, Poultices and Cerates
09/30/14 72
73
The Past: Adhesives
Example of plaster formula (1909)
Rubber 20 grams
Petrolatum 20 grams
Lead Plaster 960 grams
To make, 1000 gramsAdd any one of the following Belladonna Leaves,
Oleoresin of Capsicum, Mercury, Opium, Soap
09/30/14 73
74
The Past
The last 150 years:• Electrically assisted applications first occurred
in late 1800s and in early 1900s.• Rubber became available in the 1800s• Nitroglycerin was applied topically as an
ointment for delivery to the bloodstream in the 1950 to present.
• Belladonna, capsicum, mustard and salicylic acid plasters
09/30/14 74
The Past
75
The Present Day
• 1970-- Alza Research (US) began first development of the modern transdermal
• 1980-- Scopolamine first transdermal reached US
• 2002– Many Rx and non-RX products in US market.
• Transdermals deliver drugs from a few hours up to 7 days.
09/30/14 75